OrbusNeich revealed their next generation Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) live at the 6th Asian Interventional Cardiovascular Therapeutics 2010 (AICT) in Singapore, 2nd July 2010.
Huay Cheem Tan of the National University Hospital in Singapore, performed the case at the hospital’s Heart Centre on a 56 year old male patient who had a single lesion in the left circumflex artery. The Combo Stent placed was 3.0 mm in diameter by 18 mm in length.
“We have had a very positive experience with the Genous stent in patients with ST-elevation myocardial infarction, or STEMI, where the prohealing approach of Genous technology has safely addressed concerns that the use of drug-eluting stents in this subgroup may delay stent endothelialisation and increase the likelihood of stent thrombosis,” said Dr. Tan. “Now the Combo Stent, by combining the Genous technology with a low dose drug elution, can potentially make drug-eluting stents safer.”
The latest development in the OrbusNeich’s advances into stent technology, the Genous stent is currently being tested in a prospective, randomised, multicentre study called REMEDEE (Randomised Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) to demonstrate its safety and effectiveness compared to the TAXUS Liberté paclitaxel-eluting stent, a drug-eluting stent (DES), in the treatment of single de novo native coronary lesions ranging in diameter from ≥ 2.5 mm to ≤ 3.5 mm and ≤ 20 mm in length. The study has currently enrolled over half of the planned 180 patients at 20 sites in Asia, Australia, Europe and South America.
Commercially available in over 60 countries since 2005, the Combo Stent combines the pro-healing technology used in the company’s Genous Bio-engineered R stent for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation.
Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.